Cytiva v. JSR Corp.: Federal Circuit Splits Decision on Protein A Chromatography Patents
Cytiva Bioprocess R&D AB appealed a patentability challenge brought by JSR Corporation and JSR Life Sciences over three US patents covering Protein A-derived chromatography ligands for antibody isolation. The Federal Circuit issued a mixed ruling — affirming in part and reversing in part — across a 527-day appellate proceeding closing in December 2024.
A split Federal Circuit verdict over biologic purification IP
Cytiva Bioprocess R&D AB, a GE Healthcare-heritage bioprocessing company and holder of three US patents directed to Staphylococcus aureus Protein A domain C chromatography ligands, faced a patentability challenge from JSR Corporation and its US subsidiary JSR Life Sciences LLC — a competing supplier of bioprocess chromatography resins. The dispute centred on invalidity and cancellation actions across US10875007B2, US10343142B2, and US10213765B2, each protecting distinct aspects of engineered Protein A ligands used in industrial antibody purification.
The Federal Circuit issued an affirmed-in-part and reversed-in-part ruling on 4 December 2024, following 527 days of appellate proceedings. A mixed judgment of this nature means that some patent claims or validity determinations from the tribunal below were upheld while others were overturned. The practical effect is that Cytiva retains enforceable rights on the affirmed claims while losing ground on those reversed — and JSR’s challenge succeeded only partially, leaving neither party with a clean outcome.
The 527-day duration and involvement of six counsel for JSR suggests the complexity of the underlying validity record across three related patents, likely involving prior art disputes, claim construction, and written description challenges typical of biologic process patents. The public record does not disclose which specific claims survived or which were cancelled, meaning the precise scope of Cytiva’s remaining exclusivity in Protein A affinity chromatography requires direct review of the Federal Circuit opinion. What remains commercially significant is that JSR’s challenge only partially dismantled Cytiva’s portfolio.
Filing to Mixed Judgment in 527 days
527-day appeal — above the Federal Circuit median for patent validity disputes
Federal Circuit splits the verdict: what affirmed-in-part, reversed-in-part means
What ‘affirmed-in-part, reversed-in-part’ means at the Federal Circuit
An affirmed-in-part, reversed-in-part ruling means the Federal Circuit found the tribunal below was correct on some issues but committed reversible error on others. It is not a wholesale win for either party. The court applies de novo review to claim construction and legal invalidity questions, and clear-error review to factual findings — meaning errors must be more than minor to trigger a reversal.
Mixed appellate dispositionCytiva retains enforceability — but on a narrowed footing
Cytiva’s Protein A chromatography patent portfolio survives in part: the affirmed portions confirm that at least some claims withstood JSR’s invalidity challenge and remain enforceable. However, the reversal of other portions means certain claims or determinations were overturned, potentially narrowing Cytiva’s exclusivity zone. Patent holders in this position typically face a reduced but still meaningful enforcement position going forward.
Partial enforceability confirmedJSR partially succeeds but fails to eliminate Cytiva’s IP position
JSR Corporation and JSR Life Sciences achieved a partial victory: the reversed portions represent claims or validity findings they successfully challenged. However, the affirmance of remaining claims means JSR could not fully clear the IP landscape for its competing chromatography resin products. The company may face continued infringement exposure on surviving Cytiva claims, and further appellate options — such as en banc or Supreme Court review — face a high bar.
Challenge partially succeedsMixed verdict sustains IP tension in the antibody purification market
The Protein A affinity chromatography segment is a critical bottleneck in biologics manufacturing. A split Federal Circuit ruling leaves market participants — biosimilar manufacturers, CDMOs, and resin suppliers — in a position of continued uncertainty. Surviving Cytiva claims may restrict JSR’s commercial freedom in the antibody purification space, while the reversed claims may open design-around opportunities. Companies operating in this space should reassess FTO positions in light of the specific claims that survived.
Biologics IP landscape remains contestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cytiva Bioprocess R & D, AB | Individual | Bioprocessing R&D firm — holder of US10875007B2, US10343142B2, and US10213765B2Search in Eureka ↗ |
| Defendant | JSR Corporation | Company | JSR Corporation and JSR Life Sciences LLC — bioprocess chromatography resin suppliersSearch in Eureka ↗ |
| Co-Defendant | Jsr Life Sciences, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | David M. Krinsky | Attorney | Counsel for Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly LLP | Law Firm | Representing Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Defendant counsel | Eric William Dittmann Esq. | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Isaac S. Ashkenazi Esq. | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Michael Wolfe | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Phillip W. Citroen | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Stephen Blake Kinnaird | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s ‘affirmed-in-part and reversed-in-part’ disposition on a basis of mixed judgment reflects a granular review of the PTAB or lower tribunal’s validity determinations across three separate patent families. In patentability appeals, the court applies de novo review to legal conclusions and clear-error review to underlying fact-finding. A split outcome of this kind typically results from differential prior art records across claims — some claims surviving obviousness or anticipation analysis while others do not. Neither party can characterise this as a decisive victory, and the affirmed claims now carry heightened presumptive validity.
US10875007B2, US10343142B2 & US10213765B2 — Protein A Domain C Chromatography Ligands
The three patents at issue — US10875007B2, US10343142B2, and US10213765B2 — cover chromatography ligands derived from domain C of Staphylococcus aureus Protein A, engineered for use in affinity chromatography columns to isolate and purify monoclonal antibodies. Application numbers suggest filings between 2017 and 2019, corresponding to a period of intense innovation in next-generation Protein A resin chemistry aimed at improving alkaline stability, binding capacity, and CIP tolerance for industrial bioprocessing.
Protein A affinity chromatography is the industry-standard first-step purification platform for monoclonal antibodies and biosimilars, representing a multi-billion dollar resin market. Patents covering specific domain engineering approaches — particularly alkaline-stable variants — are among the most commercially contested in the bioprocessing sector. Cytiva (formerly GE Healthcare Life Sciences) and JSR represent two of the leading global resin suppliers, making this dispute directly relevant to any CDMO, biosimilar developer, or mAb manufacturer selecting or qualifying a chromatography platform.
Should your team run an FTO against US10875007B2 and the Cytiva Protein A portfolio?
Any organisation developing, manufacturing, or commercialising Protein A-derived affinity chromatography resins — whether for mAb purification, biosimilar production, or CDMO platform qualification — should conduct a targeted FTO analysis against the surviving claims from this Federal Circuit ruling. The mixed disposition means that some claims were invalidated but others now carry appellate-level validation. Assuming blanket clearance based on JSR’s partial success would be a material risk management error.
PatSnap Eureka’s FTO Search Agent can map your specific ligand engineering approach, domain variant, or resin product against the claim language confirmed by the Federal Circuit. Eureka cross-references prosecution history, related family members, and cited prior art to identify whether your product falls within or outside surviving claim scope — generating a structured FTO report that R&D and regulatory teams can act on before committing to commercial-scale manufacturing.
Run a freedom-to-operate analysis on US10875007B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent validity appeals in bioprocessing and biologics
Cases involving Protein A chromatography ligand patents and Federal Circuit patentability appeals in the biologics purification sector — court: Court of Appeals for the Federal Circuit.
What this case signals for the bioprocessing IP landscape
A split Federal Circuit ruling over Protein A chromatography patents has lasting implications for antibody purification IP strategy and resin supplier competition.
Split decisions on related patents signal complex prior art landscapes
When the Federal Circuit issues mixed rulings across a family of related patents, it typically signals that prior art or written description deficiencies affect some claims but not others. Bioprocessing patent holders should audit claim differentiation across co-pending families to ensure each claim set has independent validity support.
JSR’s partial success may not resolve its FTO concerns in antibody purification
Reversing some claims while affirming others leaves JSR Life Sciences exposed to infringement assertions on surviving Cytiva claims. CDMOs and resin suppliers operating in the Protein A affinity chromatography space should conduct updated FTO analyses against the specific claims the Federal Circuit affirmed before scaling commercial activity.
AB v JSR — key questions answered
The Federal Circuit issued an affirmed-in-part and reversed-in-part ruling on 4 December 2024 (Case 23-2075). This means some validity determinations from the lower tribunal were upheld and others were overturned across Cytiva’s three Protein A chromatography patents. Neither party achieved a clean victory.
Three US patents were asserted: US10875007B2 (App. No. 16/443600), US10343142B2 (App. No. 16/189894), and US10213765B2 (App. No. 15/603285). All three cover chromatography ligands derived from domain C of Staphylococcus aureus Protein A, used for antibody isolation and purification.
Cytiva retains enforceable rights over the claims the Federal Circuit affirmed, which now carry appellate-level validation. However, the reversed portions mean certain claims or validity determinations were overturned — potentially narrowing the scope of exclusivity. The exact claims surviving require review of the full Federal Circuit opinion.
Not comprehensively. While JSR partially succeeded in invalidating certain Cytiva claims, the Federal Circuit affirmed other claims, which may still cover JSR’s commercial Protein A resin products. JSR and any third party in this space should conduct an updated FTO analysis against the specific surviving claim scope before drawing commercial conclusions.
The 527-day duration likely reflects the complexity of the underlying record — three separate patents with distinct claim sets, potentially contested prior art across multiple validity grounds including obviousness and written description. The involvement of six counsel for JSR further suggests a heavily briefed record. The Federal Circuit’s mixed outcome is consistent with a complex multi-patent appeal requiring granular claim-by-claim analysis.
PatSnap Eureka searches patents and litigation data to answer instantly.